1
|
Delgado‐Dolset MI, Obeso D, Rodríguez‐Coira J, Tarin C, Tan G, Cumplido JA, Cabrera A, Angulo S, Barbas C, Sokolowska M, Barber D, Carrillo T, Villaseñor A, Escribese MM. Understanding uncontrolled severe allergic asthma by integration of omic and clinical data. Allergy 2022; 77:1772-1785. [PMID: 34839541 DOI: 10.1111/all.15192] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 10/04/2021] [Accepted: 11/02/2021] [Indexed: 12/19/2022]
Abstract
BACKGROUND Asthma is a complex, multifactorial disease often linked with sensitization to house dust mites (HDM). There is a subset of patients that does not respond to available treatments, who present a higher number of exacerbations and a worse quality of life. To understand the mechanisms of poor asthma control and disease severity, we aim to elucidate the metabolic and immunologic routes underlying this specific phenotype and the associated clinical features. METHODS Eighty-seven patients with a clinical history of asthma were recruited and stratified in 4 groups according to their response to treatment: corticosteroid-controlled (ICS), immunotherapy-controlled (IT), biologicals-controlled (BIO) or uncontrolled (UC). Serum samples were analysed by metabolomics and proteomics; and classifiers were built using machine-learning algorithms. RESULTS Metabolomic analysis showed that ICS and UC groups cluster separately from one another and display the highest number of significantly different metabolites among all comparisons. Metabolite identification and pathway enrichment analysis highlighted increased levels of lysophospholipids related to inflammatory pathways in the UC patients. Likewise, 8 proteins were either upregulated (CCL13, ARG1, IL15 and TNFRSF12A) or downregulated (sCD4, CCL19 and IFNγ) in UC patients compared to ICS, suggesting a significant activation of T cells in these patients. Finally, the machine-learning model built including metabolomic and clinical data was able to classify the patients with an 87.5% accuracy. CONCLUSIONS UC patients display a unique fingerprint characterized by inflammatory-related metabolites and proteins, suggesting a pro-inflammatory environment. Moreover, the integration of clinical and experimental data led to a deeper understanding of the mechanisms underlying UC phenotype.
Collapse
Affiliation(s)
- María Isabel Delgado‐Dolset
- Institute of Applied Molecular Medicine (IMMA) Department of Basic Medical Sciences Facultad de Medicina Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
- Centre for Metabolomics and Bioanalysis (CEMBIO) Department of Chemistry and Biochemistry Facultad de Farmacia Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
| | - David Obeso
- Institute of Applied Molecular Medicine (IMMA) Department of Basic Medical Sciences Facultad de Medicina Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
- Centre for Metabolomics and Bioanalysis (CEMBIO) Department of Chemistry and Biochemistry Facultad de Farmacia Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
| | - Juan Rodríguez‐Coira
- Institute of Applied Molecular Medicine (IMMA) Department of Basic Medical Sciences Facultad de Medicina Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
- Centre for Metabolomics and Bioanalysis (CEMBIO) Department of Chemistry and Biochemistry Facultad de Farmacia Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
- Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Zurich Switzerland
| | - Carlos Tarin
- Institute of Applied Molecular Medicine (IMMA) Department of Basic Medical Sciences Facultad de Medicina Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
| | - Ge Tan
- Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Zurich Switzerland
| | - José A. Cumplido
- Hospital Universitario de Gran Canaria Doctor Negrin Las Palmas de Gran Canaria Spain
| | - Ana Cabrera
- Hospital Universitario de Gran Canaria Doctor Negrin Las Palmas de Gran Canaria Spain
| | - Santiago Angulo
- Department of Applied Mathematics and Statistics Universidad San Pablo‐CEU CEU Universities Madrid Spain
| | - Coral Barbas
- Centre for Metabolomics and Bioanalysis (CEMBIO) Department of Chemistry and Biochemistry Facultad de Farmacia Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
| | - Milena Sokolowska
- Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Zurich Switzerland
| | - Domingo Barber
- Institute of Applied Molecular Medicine (IMMA) Department of Basic Medical Sciences Facultad de Medicina Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
| | - Teresa Carrillo
- Hospital Universitario de Gran Canaria Doctor Negrin Las Palmas de Gran Canaria Spain
| | - Alma Villaseñor
- Institute of Applied Molecular Medicine (IMMA) Department of Basic Medical Sciences Facultad de Medicina Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
| | - María M. Escribese
- Institute of Applied Molecular Medicine (IMMA) Department of Basic Medical Sciences Facultad de Medicina Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Madrid Spain
| |
Collapse
|
2
|
Pedrosa L, Fernández-Miranda I, Pérez-Callejo D, Quero C, Rodríguez M, Martín-Acosta P, Gómez S, González-Rincón J, Santos A, Tarin C, García JF, García-Arroyo FR, Rueda A, Camacho FI, García-Cosío M, Heredero A, Llanos M, Mollejo M, Piris-Villaespesa M, Gómez-Codina J, Yanguas-Casás N, Sánchez A, Piris MA, Provencio M, Sánchez-Beato M. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. Sci Rep 2021; 11:1886. [PMID: 33479306 PMCID: PMC7820010 DOI: 10.1038/s41598-020-80376-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Accepted: 12/21/2020] [Indexed: 12/16/2022] Open
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative, multi-omic analyses had led to identifying overlapping genetic DLBCL subtypes. We used targeted massive sequencing to analyze 84 diagnostic samples from a multicenter cohort of patients with DLBCL treated with rituximab-containing therapies and a median follow-up of 6 years. The most frequently mutated genes were IGLL5 (43%), KMT2D (33.3%), CREBBP (28.6%), PIM1 (26.2%), and CARD11 (22.6%). Mutations in CD79B were associated with a higher risk of relapse after treatment, whereas patients with mutations in CD79B, ETS1, and CD58 had a significantly shorter survival. Based on the new genetic DLBCL classifications, we tested and validated a simplified method to classify samples in five genetic subtypes analyzing the mutational status of 26 genes and BCL2 and BCL6 translocations. We propose a two-step genetic DLBCL classifier (2-S), integrating the most significant features from previous algorithms, to classify the samples as N12-S, EZB2-S, MCD2-S, BN22-S, and ST22-S groups. We determined its sensitivity and specificity, compared with the other established algorithms, and evaluated its clinical impact. The results showed that ST22-S is the group with the best clinical outcome and N12-S, the more aggressive one. EZB2-S identified a subgroup with a worse prognosis among GCB-DLBLC cases.
Collapse
Affiliation(s)
- Lucía Pedrosa
- Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain.,PhD Program in Molecular Biosciences, Doctoral School, Universidad Autónoma de Madrid, Madrid, Spain
| | - Ismael Fernández-Miranda
- Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain.,PhD Program in Molecular Biosciences, Doctoral School, Universidad Autónoma de Madrid, Madrid, Spain
| | - David Pérez-Callejo
- Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.,PhD Program in Medicine and Surgery, Doctoral School, Universidad Autónoma de Madrid, Madrid, Spain
| | - Cristina Quero
- Medical Oncology Department, Hospital Universitario Virgen de La Victoria, Malaga, Spain
| | - Marta Rodríguez
- Pathology Department, Hospital Fundación Jiménez Díaz, Madrid, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Paloma Martín-Acosta
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.,Molecular Pathology Laboratory, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain
| | - Sagrario Gómez
- Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain
| | - Julia González-Rincón
- Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Adrián Santos
- Molecular Pathology Laboratory, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain
| | - Carlos Tarin
- Bioinformatics Unit, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.,Basic Medical Sciences, Faculty of Medicine, Universidad CEU San Pablo, Madrid, Spain
| | - Juan F García
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, MD Anderson Cancer Center, Madrid, Spain
| | | | - Antonio Rueda
- Medical Oncology Department, Hospitales Universitarios Regional y Virgen de La Victoria, IBIMA, Malaga, Spain
| | | | | | - Ana Heredero
- Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain
| | - Marta Llanos
- Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain
| | - Manuela Mollejo
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, Complejo Hospitalario de Toledo, Toledo, Spain
| | | | - José Gómez-Codina
- Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Natalia Yanguas-Casás
- Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain
| | - Antonio Sánchez
- Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
| | - Miguel A Piris
- Pathology Department, Hospital Fundación Jiménez Díaz, Madrid, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - Mariano Provencio
- Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
| | - Margarita Sánchez-Beato
- Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain. .,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
| |
Collapse
|
3
|
Molina-Sánchez P, Jorge I, Martinez-Pinna R, Blanco-Colio LM, Tarin C, Torres-Fonseca MM, Esteban M, Laustsen J, Ramos-Mozo P, Calvo E, Lopez JA, Ceniga MVD, Michel JB, Egido J, Andrés V, Vazquéz J, Meilhac O, Burillo E, Lindholt JS, Martin-Ventura JL. ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression. Thromb Haemost 2017; 113:1335-46. [DOI: 10.1160/th14-10-0874] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Accepted: 01/21/2015] [Indexed: 12/18/2022]
Abstract
SummaryAbdominal aortic aneurysm (AAA) evolution is unpredictable, and there is no therapy except surgery for patients with an aortic size > 5 cm (large AAA). We aimed to identify new potential biomarkers that could facilitate prognosis and treatment of patients with AAA. A differential quantitative proteomic analysis of plasma proteins was performed in AAA patients at different stages of evolution [small AAA (aortic size=3�5cm) vs large AAA] using iTRAQ labelling, highthroughput nano-LC-MS/MS and a novel multi-layered statistical model. Among the proteins identified, ApoA-I was decreased in patients with large AAA compared to those with small AAA. These results were validated by ELISA on plasma samples from small (n=90) and large AAA (n=26) patients (150 ± 3 vs 133 ± 5 mg/dl, respectively, p< 0.001). ApoA-I levels strongly correlated with HDL-Cholesterol (HDL-C) concentration (r=0.9, p< 0.001) and showed a negative correlation with aortic size (r=-0.4, p< 0.01) and thrombus volume (r=-0.3, p< 0.01), which remained significant after adjusting for traditional risk factors. In a prospective study, HDL-C independently predicted aneurysmal growth rate in multiple linear regression analysis (n=122, p=0.008) and was inversely associated with need for surgical repair (Adjusted hazard ratio: 0.18, 95 % confidence interval: 0.04�0.74, p=0.018). In a nation-wide Danish registry, we found lower mean HDL-C concentration in large AAA patients (n=6,560) compared with patients with aorto-iliac occlusive disease (n=23,496) (0.89 ± 2.99 vs 1.59 ± 5.74 mmol/l, p< 0.001). Finally, reduced mean aortic AAA diameter was observed in AngII-infused mice treated with ApoA-I mimetic peptide compared with saline-injected controls. In conclusion, ApoAI/ HDL-C systemic levels are negatively associated with AAA evolution. Therapies targeting HDL functionality could halt AAA formation.
Collapse
|
4
|
Madrigal-Matute J, Martinez-Pinna R, Ramos-Mozo P, Blanco-Colio L, Moreno J, Tarin C, Burillo E, Fernandez-Garcia C, Egido J, Meilhac O, Michel JB, Martin-Ventura J. Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: Detoxifying mechanisms and potential therapeutic options. Thromb Haemost 2017; 108:435-42. [DOI: 10.1160/th12-04-0248] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2012] [Accepted: 06/21/2012] [Indexed: 12/15/2022]
Abstract
SummaryOxidative stress is involved in the chronic pathological vascular remodelling of both abdominal aortic aneurysm and occlusive atherosclerosis. Red blood cells (RBCs), leukocytes and platelets present in both, aneurysmal intraluminal thrombus and intraplaque haemorraghes, could be involved in the redox imbalance inside diseased arterial tissues. RBCs haemolysis may release the pro-oxidant haemoglobin (Hb), which transfers heme to tissue and low-density lipoproteins. Heme-iron potentiates molecular, cell and tissue toxicity mediated by leukocytes and other sources of reactive oxygen species (ROS). Polymorphonuclear neutrophils release myeloperoxidase and, along with activated platelets, produce superoxide mediated by NADPH oxidase, causing oxidative damage. In response to this pro-oxidant milieu, several anti-oxidant molecules of plasma or cell origin can prevent ROS production. Free Hb binds to haptoglobin (Hp) and once Hp-Hb complex is endocytosed by CD163, liberated heme is converted into less toxic compounds by heme oxygenase-1. Iron homeostasis is mainly regulated by transferrin, which transports ferric ions to other cells. Transferrin-bound iron is internalised via endocytosis mediated by transferrin receptor. Once inside the cell, iron is mainly stored by ferritin. Other non hemo-iron related antioxidant enzymes (e.g. superoxide dismutase, catalase, thioredoxin and peroxiredoxin) are also involved in redox modulation in vascular remodelling. Oxidative stress is a main determinant of chronic pathological remodelling of the arterial wall, partially linked to the presence of RBCs, leukocytes, platelets and oxidised fibrin within tissue and to the imbalance between pro-/anti-oxidant molecules. Understanding the complex mechanisms underlying redox imbalance could help to define novel potential targets to decrease atherothrombotic risk.
Collapse
|
5
|
Tarin C, Carril M, Martin-Ventura JL, Markuerkiaga I, Padro D, Llamas-Granda P, Moreno JA, García I, Genicio N, Plaza-Garcia S, Blanco-Colio LM, Penades S, Egido J. Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI. Sci Rep 2015; 5:17135. [PMID: 26616677 PMCID: PMC4663748 DOI: 10.1038/srep17135] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Accepted: 10/09/2015] [Indexed: 12/23/2022] Open
Abstract
CD163 is a membrane receptor expressed by macrophage lineage. Studies performed in atherosclerosis have shown that CD163 expression is increased at inflammatory sites, pointing at the presence of intraplaque hemorrhagic sites or asymptomatic plaques. Hence, imaging of CD163 expressing macrophages is an interesting strategy in order to detect atherosclerotic plaques. We have prepared a targeted probe based on gold-coated iron oxide nanoparticles vectorized with an anti-CD163 antibody for the specific detection of CD163 by MRI. Firstly, the specificity of the targeted probe was validated in vitro by incubation of the probe with CD163(+) or (-) macrophages. The probe was able to selectively detect CD163(+) macrophages both in human and murine cells. Subsequently, the targeted probe was injected in 16 weeks old apoE deficient mice developing atherosclerotic lesions and the pararenal abdominal aorta was imaged by MRI. The accumulation of probe in the site of interest increased over time and the signal intensity decreased significantly 48 hours after the injection. Hence, we have developed a highly sensitive targeted probe capable of detecting CD163-expressing macrophages that could provide useful information about the state of the atheromatous lesions.
Collapse
Affiliation(s)
- Carlos Tarin
- Laboratorio de Patología Vascular y Renal. IIS Fundación Jiménez Díaz, Universidad Autónoma. Av. Reyes Católicos 2, 28040, Madrid, Spain
| | - Monica Carril
- Laboratorio de Gliconanotecnología. Biofunctional Nanomaterials Unit. CIC biomaGUNE. Paseo Miramón, 182, 20009, San Sebastián, Spain.,Ikerbasque, Basque Foundation for Science, 48011, Bilbao, Spain
| | - Jose Luis Martin-Ventura
- Laboratorio de Patología Vascular y Renal. IIS Fundación Jiménez Díaz, Universidad Autónoma. Av. Reyes Católicos 2, 28040, Madrid, Spain
| | - Irati Markuerkiaga
- Molecular Imaging Unit, CIC biomaGUNE, PaseoMiramón 182, 20009, San Sebastián, Spain
| | - Daniel Padro
- Molecular Imaging Unit, CIC biomaGUNE, PaseoMiramón 182, 20009, San Sebastián, Spain
| | - Patricia Llamas-Granda
- Laboratorio de Patología Vascular y Renal. IIS Fundación Jiménez Díaz, Universidad Autónoma. Av. Reyes Católicos 2, 28040, Madrid, Spain
| | - Juan Antonio Moreno
- Laboratorio de Patología Vascular y Renal. IIS Fundación Jiménez Díaz, Universidad Autónoma. Av. Reyes Católicos 2, 28040, Madrid, Spain
| | - Isabel García
- Laboratorio de Gliconanotecnología. Biofunctional Nanomaterials Unit. CIC biomaGUNE. Paseo Miramón, 182, 20009, San Sebastián, Spain.,Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo Miramón 182, 20009, San Sebastián, Spain
| | - Nuria Genicio
- Laboratorio de Gliconanotecnología. Biofunctional Nanomaterials Unit. CIC biomaGUNE. Paseo Miramón, 182, 20009, San Sebastián, Spain
| | - Sandra Plaza-Garcia
- Molecular Imaging Unit, CIC biomaGUNE, PaseoMiramón 182, 20009, San Sebastián, Spain
| | - Luis Miguel Blanco-Colio
- Laboratorio de Patología Vascular y Renal. IIS Fundación Jiménez Díaz, Universidad Autónoma. Av. Reyes Católicos 2, 28040, Madrid, Spain
| | - Soledad Penades
- Laboratorio de Gliconanotecnología. Biofunctional Nanomaterials Unit. CIC biomaGUNE. Paseo Miramón, 182, 20009, San Sebastián, Spain.,Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo Miramón 182, 20009, San Sebastián, Spain
| | - Jesus Egido
- Laboratorio de Patología Vascular y Renal. IIS Fundación Jiménez Díaz, Universidad Autónoma. Av. Reyes Católicos 2, 28040, Madrid, Spain
| |
Collapse
|
6
|
Teutsch T, Mesch M, Giessen H, Tarin C. Dynamic modeling of the hydrogel molecular filter in a metamaterial biosensing system for glucose concentration estimation. Annu Int Conf IEEE Eng Med Biol Soc 2015; 2014:2081-4. [PMID: 25570394 DOI: 10.1109/embc.2014.6944026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We present a novel concept for ophthalmic glucose sensing using a biosensing system that consists of plasmonic dipole metamaterial covered by a layer of functionalized hydrogel. The metamaterial together with the hydrogel can be integrated into a contact lens. This optical sensor changes its properties such as reflectivity upon the ambient glucose concentration, which allows in situ measurements in the eye. The functionalization of the sensor with hydrogel allows for a glucose-specific detection, providing both selectivity and sensitivity. As a result of the presented work we derive a dynamic model of the hydrogel that can be used for further simulation studies.
Collapse
|
7
|
Teutsch T, Mesch M, Giessen H, Tarin C. Discrete wavelength selection for the optical readout of a metamaterial biosensing system for glucose concentration estimation via a support vector regression model. Annu Int Conf IEEE Eng Med Biol Soc 2015; 2015:6421-6424. [PMID: 26737762 DOI: 10.1109/embc.2015.7319862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
In this contribution, a method to select discrete wavelengths that allow an accurate estimation of the glucose concentration in a biosensing system based on metamaterials is presented. The sensing concept is adapted to the particular application of ophthalmic glucose sensing by covering the metamaterial with a glucose-sensitive hydrogel and the sensor readout is performed optically. Due to the fact that in a mobile context a spectrometer is not suitable, few discrete wavelengths must be selected to estimate the glucose concentration. The developed selection methods are based on nonlinear support vector regression (SVR) models. Two selection methods are compared and it is shown that wavelengths selected by a sequential forward feature selection algorithm achieves an estimation improvement. The presented method can be easily applied to different metamaterial layouts and hydrogel configurations.
Collapse
|
8
|
Martinez-Pinna R, Madrigal-Matute J, Tarin C, Burillo E, Esteban-Salan M, Pastor-Vargas C, Lindholt JS, Lopez JA, Calvo E, de Ceniga MV, Meilhac O, Egido J, Blanco-Colio LM, Michel JB, Martin-Ventura JL. Proteomic Analysis of Intraluminal Thrombus Highlights Complement Activation in Human Abdominal Aortic Aneurysms. Arterioscler Thromb Vasc Biol 2013; 33:2013-20. [DOI: 10.1161/atvbaha.112.301191] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Roxana Martinez-Pinna
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Julio Madrigal-Matute
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Carlos Tarin
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Elena Burillo
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Margarita Esteban-Salan
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Carlos Pastor-Vargas
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Jes S. Lindholt
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Juan A. Lopez
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Enrique Calvo
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Melina Vega de Ceniga
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Olivier Meilhac
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Jesus Egido
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Luis M. Blanco-Colio
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Jean-Baptiste Michel
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| | - Jose L. Martin-Ventura
- From the Vascular Research Lab (R.M.-P., J.M.-M., C.T., E.B., J.E., L.M.B.-C., J.L.M.-V.) and Immunology Lab (C.P.-V.), IIS-Fundación Jiménez Diaz-Autonoma University, Madrid, Spain; Hospital de Cruces (M.E.-S.) and Hospital Galdakao, Vizcaya, Spain (M.V.d.C.); Departments of Cardiovascular and Thoracic Surgery, University Hospital of Odense and Viborg, Odense, Denmark (J.S.L.); Unidad de Proteómica, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (J.A.L., E.C.); and Inserm, U698,
| |
Collapse
|
9
|
Tarin C, Lavin B, Gomez M, Saura M, Diez-Juan A, Zaragoza C. The extracellular matrix metalloproteinase inducer EMMPRIN is a target of nitric oxide in myocardial ischemia/reperfusion. Free Radic Biol Med 2011; 51:387-95. [PMID: 21570464 DOI: 10.1016/j.freeradbiomed.2011.04.021] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2011] [Revised: 03/29/2011] [Accepted: 04/11/2011] [Indexed: 12/20/2022]
Abstract
Nitric oxide (NO) is an important defense against myocardial ischemia/reperfusion (I/R) injury. Although matrix metalloproteinase (MMP)-mediated necrosis of cardiac myocytes is well characterized, the role of inducible NO synthase (iNOS)-derived NO in this process is poorly understood. I/R injury was increased in iNOS-deficient mice and in mice treated with 1400 W (a pharmacological iNOS inhibitor) and was associated with significantly increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and EMMPRIN-associated MMPs. Transcriptional activity of an EMMPRIN luciferase promoter reporter expressed in cardiac myocytes was inhibited by NO in a cGMP-dependent manner, and this transcriptional inhibition was abolished by mutation of a putative E2F site. Consistent with these findings, EMMPRIN null mice, in which iNOS is normally induced, are partially protected against I/R injury. Pharmacological inhibition of iNOS in EMMPRIN null mice had no additional protective effect, suggesting that EMMPRIN is a downstream target of NO. Administration of anti-EMMPRIN neutralizing antibodies partly reduced the excess heart damage and MMP-9 expression induced by I/R in iNOS null mice, indicating that regulation of EMMPRIN is an important mechanism of NO-mediated cardioprotection.
Collapse
Affiliation(s)
- Carlos Tarin
- Fundación Centro Nacional de Investigaciones Cardiovasculares, Madrid 28029, Spain
| | | | | | | | | | | |
Collapse
|
10
|
Saura M, Tarin C, Zaragoza C. Recent insights into the implication of nitric oxide in osteoblast differentiation and proliferation during bone development. ScientificWorldJournal 2010; 10:624-32. [PMID: 20419275 PMCID: PMC5763674 DOI: 10.1100/tsw.2010.58] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Bone tissue renovation is a dynamic event in which osteoblasts and osteoclasts are responsible for the turnover between bone formation and bone resorption, respectively. During bone development, extracellular matrix remodeling is required for osteoblast differentiation and the process is largely mediated by the proteolytic activity of extracellular matrix metalloproteinases (MMPs), which play a fundamental role in osteoblast migration, unmineralized matrix degradation, and cell invasion. The recent advances towards investigation in osteogenesis have provided significant information about the transcriptional regulation of several genes, including MMPs, by the expression of crucial transcription factors like NFAT, ATF4, osterix, TAZ, and Cbfa-1–responsive elements. Evidence from gene knock-out studies have shown that bone formation is, at least in part, mediated by nitric oxide (NO), since mice deficient in endothelial nitric oxide synthase (eNOS) and mice deficient in the eNOS downstream effector (cGMP)-dependent protein kinase (PKG) show bone abnormalities, while inducible NOS (iNOS) null mice also show imbalances in bone osteogenesis and abnormalities in bone healing. Recently, in vitro data showed that Cbfa-1 and the MAPK pathways were crucial for osteoblastic cell differentiation, and NO was found to play a significant role. This article sheds light on some of the mechanisms that may influence NO-mediated actions in bone development.
Collapse
Affiliation(s)
- Marta Saura
- Departamento de Fisiologia, Facultad de Medicina, Universidad de Alcala, Madrid, Spain
| | | | | |
Collapse
|
11
|
|
12
|
Descatha A, Dolveck F, Tarin C, Gillot J, Cazzola P, Bourrillon M, Paquet C, Gillot T, Baer M, Fletcher D. Enseignement du rôle du médecin du travail dans la gestion d’une crise par la pratique : exemple d’un exercice à victimes multiples dans une usine pétrochimique. ARCH MAL PROF ENVIRO 2006. [DOI: 10.1016/s1775-8785(06)78073-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|